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The role of hyaluronan (HA), serum-derived HA-associated protein (SHAP)-HA complex and hyaluronan synthase (HAS) in
endometrial carcinomas was investigated. The relationship of metalloproteinase (MMP) and its inhibitor (TIMP) with HA
and the SHAP-HA complex was also examined. The expression of HAS1 was related to the depth of myometrial invasion and
lymph-vascular space involvement. The serum levels of HA, SHAP-HA complex, MMP-9, and TIMP-1 were increased in related
with the depth of myometrial invasion, histological grade and lymph-vascular space involvement. They were also higher in the
HAS1-positive group compared to -negative group. The serum concentrations of HA and SHAP-HA complex had a signiﬁcant
correlationwiththeMMP-9andTIMP-1.The patients withelevated SHAP-HAcomplex hadthe shorter disease-free survival.The
multivariate analysis revealed that the SHAP-HA complex was the independent variable for disease-free survival of endometrial
cancer patients. In conclusion, the elevation of serum SHAP-HA complex depended on the HAS1 expression and the SHAP-HA
complex is a useful marker to predict disease recurrence in endometrial cancer patients. The SHAP-HA complex may promote
the lymph-vascular space involvement and the synthesis and activation of MMP-9 and TIMP-1 in the progression of endometrial
cancer.
1.Introduction
The incidence rate for endometrial cancer has been increas-
ing in Japan [1]. Clinicopathological studies show that
poor prognosis is related to cervical invasion of malignant
cells, deep myometrial invasion of malignant cells, lymph
node metastasis, and lymph-vascular space involvement of
malignant cells [2, 3] .T h em u l t i s t a g ep r o c e s so ft u m o r
invasion and metastasis depends on several mechanisms,
including the stimulation of cell growth by growth fac-
tors, destruction of the extracellular matrix by proteolytic
enzymes, neovascularization due to the presence of angio-
genic factors, and cell to cell or stroma adhesion regulated by
cell adhesion molecules.
Hyaluronan (HA) is an extracellular polysaccharide typ-
ically present in the extracellular matrix of some epithelial
and neuraltissues. HAisparticularly abundantin connective
tissues. HA controls cell migration, diﬀerentiation, and pro-
liferation, thereby inﬂuencing tissue morphogenesis, wound
healing, and tumor growth [4, 5]. HA levels correlate with
the invasiveness and metastatic capacity of tumor cells [6].
IncreasedHAconcentrationsmayhelpinvasionbyproviding2 Obstetrics and Gynecology International
alessdensematrix forcancercells[7],stimulatingcancercell
motility, and forming an immunoprotective coat for cancer
cells [8].
Three mammalian hyaluronan synthase (HAS) genes,
HAS1, HAS2, and HAS3, are involved in hyaluronan biosyn-
thesis[9],andtheirexpressionsvarydependingupontissue-,
age- and pathophysiological diﬀerencesand are important to
investigate the biological function of hyaluronan, especially
in tumor cell malignancy, because the overexpression of
HAS makes tumor cells more aggressive with signiﬁcant
diﬀerences in the malignant activity among the three HAS
genes [10]. The three isoforms of HAS have been shown
to synthesize distinct types of hyaluronans with diﬀerent
structural characteristics and functions [9].
Associations with various HA-binding proteins, includ-
ing proteoglycans, result in tremendously diverse physiolog-
ical functions for HA. Extracellular matrix containing HA as
a major component, called HA-rich matrix, plays important
roles in regulating cellularbehavior in a variety of physiolog-
ical and pathological processes via cell-surface HA receptors,
suchasCD44andreceptorforhyaluronan-mediated motility
[11].
SHAP was originally discovered as the complex with HA
in HA-rich matrix from cultured mouse dermal ﬁbroblasts
and was found to be derived from serum supplemented to
culture media, and thereby named as serum-derived HA-
associatedproteins(SHAPs)[12,13].Then,SHAPwasfound
to correspond to the heavy chains of plasma inter-α-trypsin
inhibitor (ITI) family molecules and be covalently bound to
HA via a unique ester bond [12–14]. ITI family molecules
are synthesized by hepatocytes and secreted into the blood
at high concentrations [15]. The heavy chains of these
moleculesarederivedfrom3diﬀerentgenes,andeither1or2
ofthechainsarecovalentlyboundtothelightchain, bikunin,
to form ITI family members such as ITI, pre-α-trypsin
inhibitor, and inter-α-trypsin-like inhibitor [16]. During the
formation of SHAP-HA complexes, HA is substituted for the
chondroitin sulfate chain of bikunin, accompanied by the
release of bikunin [12, 17]. Released bikunin is excreted in
urine as urinary trypsin inhibitor (UTI).
Matrix metalloproteases (MMPs) play a crucial role in
tissueremodeling in avariety ofphysiologicalandpathologi-
cal processes, similar to the roles of HA. In malignant tumor,
HA may possibly inﬂuence the expression of MMP-9 as well
as the conversion of the inactive pro-forms to active forms
[18, 19].
We previously reported the role of HA and HAS1 in en-
dometrial cancer [20]. The expression of HAS1 and serum
HA level were related to the depth of myometrial invasion,
histological grade, and lymph-vascular space involvement.
Serum HA level was higher in the HAS1-positive group
than in the HAS1-negative group. The goal of the present
study was to determine if the levels of HA, the SHAP-HA
complex, UTI, and the immunohistochemical expression of
HAS correlate with the clinicopathological manifestations
and clinical outcome of endometrial carcinoma. The causal
relationships of the serum levels of HA and the SHAP-HA
complex with those of metalloproteinase and its inhibitor in
serum were also examined and discussed.
2.Materialsand Methods
2.1. Clinical Samples. Formalin-ﬁxed, paraﬃn-embedded
tissue, serum, and urine were obtained from 50 patientswith
endometrioid adenocarcinoma of the endometrium. All pa-
tients attended the gynecology clinic at Aichi Medical Uni-
versity Hospital and were diagnosed as stage I. Of them,
nine cases who did not undergo lymphadenectomy had no
ﬁndingsuggestingthelymphnodemetastasis inapresurgical
CTscan examination. The surgicalspecimens were evaluated
by more than one gynecologic pathologists, and they also
evaluated the immunohistochemical examination. Serum
and urine were also obtained from 50 postmenopausal
donors with the negative endometrial cytology. The mean
age of endometrial cancer patients was 57.24 ± 9.28 years,
and that of healthy women was 54.52 ± 6.34 years observed
in healthy women, which was almost the same as that of the
patients (P = 0.09). This study was approved by the regional
ethics committee of Aichi Medical University, School of
Medicine. Written informed consent was obtained from all
participants prior to study enrollment.
2.2. Immunohistochemistry. The polyclonal antibodies
against HAS1, HAS2, and HAS3 were raised in rabbits by
subcutaneous injection of the following synthetic peptides;
VRRLCRRRSGGTRVGV, corresponding to amino acids
568–582 of HAS1; CGRRKKGQQYDMVLDV, correspond-
ing to the amino acids 537–552 of HAS2; CGKKPEQYS-
LAFAEV, corresponding to amino acids 541–555 of HAS3,
which had been coupled to keyhole limpet hemocyanin. The
speciﬁcity of the puriﬁed antibodies has beenconﬁrmed [10,
21]. Immunostaining was performed by the avidin-biotin-
peroxidase complex method using a VECTASTAIN ABC kit
Elite (VectorLaboratoriesInc., Burlingame, Calif, USA).The
prepared 3μm sections were deparaﬃnized and rehydrated.
After treatment with 0.25% trypsin solution at 37◦Cf o r
10 minutes, the sections were incubated at 4◦Co v e r n i g h t
with the antibodies against HAS1, HAS2 and HAS3. The
chemogen used was 3,3 -diaminobenzidine tetrahydrochlo-
ride (Dojindo, Kumamoto, Japan). Sections were coun-
terstained with hematoxylin for microscopic examination.
Sections were deﬁned as having positive expression when
>90% of tumor cells were intensely stained.
2.3. Measurement of Serum Concentrations for HA, SHAP-
HA Complex, MMP-2, MMP-9 and TIMP-1, and Urine Con-
centration of UTI. Concentrations of HA in serum were
measured using an inhibitory enzyme-linked immunosor-
bent assay (ELISA) (Seikagaku Corp., Tokyo, Japan) [22].
Brieﬂy, HA-conjugated bovine serum albumin (BSA) plates
were washed 3 times with phosphate-buﬀered saline (PBS)
containing 0.1% Tween 20 (PBS-T). Then, 50μLs a m p l e
(diluted 1:5∼10 with PBS-T) and 50μLb i o t i n y l a t e dH A B P
(0.5μg/mL in 1% BSA/PBS-T)were appliedto each well, and
plates were incubated at 37◦C for 1h. After washing with
PBS-T, 50μL horseradish peroxidase-streptavidin (1:500)
was added to each well, and plates were further incubated at
37◦C for 1h. Color development was achieved by incubating
with 50μL of tetramethylbenzidine (TMB) solution at 37◦CObstetrics and Gynecology International 3
for 10min; then, the reaction was stopped by adding 50μL
1M HCl. Absorbance at 450/630nm (absorbance at 450nm-
absorbance at 630nm) was measured with an immuno
Mini NI-2300 spectrophotometer. Assays were performed in
triplicate.
The levels of the SHAP-HA complex in sera were de-
termined by measuring the amount of SHAPs bound to
HA using a sandwich ELISA [22]. Microtiter plates were
coated with HABP (4μg/mL in 0.1M sodium carbonate
buﬀer; pH 9.5) at 4◦C for 15h. Wells were washed twice
with 200μL PBS, followed by blocking with 200μLo f3 %
BSA in PBS-T at room temperature for 1h. After washing
the wells 3 times with 200μLP B S - T ,5 0 μLs a m p l e( s e r u m
diluted 1:5∼10 with 1% BSA/PBS-T) was added to each
well. Then, plates were incubated at 37◦Cf o r1 h .A f t e r
washing, 25μL of rabbit antihuman ITI antibody (diluted
1:3000 with 1% BSA/PBS-T) and 25μLo fH R P - c o n j u g a t e d
goat antirabbit immunoglobulins antibody (diluted 1:3000
with 1% BSA/PBS-T)were added to each well and incubated
at 37◦C for 1h. Wells were washed 3 times then were
incubated with 50μL of TMB solution at 37◦Cf o r1 0m i n .
The reaction was stopped by the addition of 50μL1MH C l ,
and absorbance at 450/650nm was measured. Assays were
performed in triplicate.
The urine levels of UTI were measured using an in-
hibitory ELISA [22]. Microtiter plates were coated with UTI
(2μg/mL in 0.1M sodium carbonate buﬀer; pH 9.5) at 4◦C
overnightandthenblockedwith3%BSAasabove.Theplates
were washed 3 times with PBS-T, then 50μL sample (urine
diluted 1:5∼10 with PBS) and 50μL anti-UTI antibodies
were applied to each well and incubated at 37◦Cf o r1 h .
Wells were washed, and 100μL HRP-conjugated goat anti-
rabbit antibody was added to each well. Plates were then
further incubated at 37◦C for 1h. After washing with PBS-
T, color development was achieved by incubation with 50μL
TMB solution at 37◦C for 10min, then the reaction was
stoppedusing50μL1MHCl.Absorbanceat450/650nmwas
measured. Assays were performed in triplicate.
Concentrations of MMP-2, MMP-9, and TIPM-1 in sera
were measured with a one-step sandwich ELISA kit for each
(Fuji Chemical Co., Toyama, Japan) as reported previously
[23–25]. A serum (10μL) was mixed with 100μLo f5 0μg/L
each antibody conjugated with HRP in 10mM sodium
phosphate buﬀer (pH 7.0) containing 10g/L BSA, 10nM
EDTA, and 0.1M NaCl. A 100μL aliquot of the mixture was
transferred to microplate well previously coated with each
antibody. The plate was incubated for 60min at room tem-
perature and then washed 3 times with PBS. Color develop-
ment was achieved by incubation with 100μLo fc i t r i ca c i d -
sodium phosphate buﬀer containing o-phenylenediamine
and hydrogen peroxide at room temperature for 20min.
The reaction was stopped with 100μL1 MH C l ,a n dt h e
absorbance at 492nm was measured. Assays were performed
in triplicate.
2.4. Statistical Analysis. The statistical signiﬁcance of diﬀer-
ences among diﬀerent categories of expression was analyzed
using the unpaired t-test, the chi-square test, and two-way
ANOVA. Pearson correlation coeﬃcient was used to test for
signiﬁcant relationships. Disease-free survival was analyzed
by the Kaplan-Meier method and log-rank test, and the
potential signiﬁcance ofpluralprognosticfactors fordisease-
free survival was analyzed by Cox proportional hazard
model. P values less than 0.05 were considered statistically
signiﬁcant.
3.Results
3.1. HAS, HA, SHAP-HA Complex, UTI, MMP-2, MMP-
9, and TIMP-1 in Relation to the Clinicopathological
Manifestations. In endometrioid adenocarcinoma of uterine
corpus, the HAS1, HAS2, and HAS3 were expressed in
tumor cells as our previous report (Figure 1)[ 20]. Of the 50
endometrial cancer cases, the positiveimmunohistochemical
expression was found in 29 cases for HAS1, 33 cases for
HAS2, and 29 cases for HAS3. The expression of HAS1 was
related to the depth of myometrial invasion and lymph-
vascular space involvement although it had no relationship
with the histological grade. On the other hand, the
expression of HAS2 and HAS3 had no relationship with the
depthofmyometrialinvasion,histologicalgrade,andlymph-
vascular space involvement (Table 1). The serum levels of
HA,theSHAP-HAcomplex,MMP-9, TIMP-1, andUTIwere
higher in the endometrial cancer group than in the control
group, while the serum MMP-2 levels had no diﬀerence
between both groups (Table 2). The serum levels of HA, the
SHAP-HA complex, MMP-9, and TIMP-1 were signiﬁcantly
increased in the patients with the deeper myometrial
invasion (Table 3). The urine levels of UTI and serum levels
of HA, the SHAP-HA, complex and TIMP-1 were higher
in the patients with the poorly diﬀerentiated (G3) tumor,
compared with the moderately diﬀerentiated (G2) tumor
and well-diﬀerentiated (G1) tumor. The serum levels of HA,
the SHAP-HA complex, MMP-9, TIMP-1, and the urine
level of UTI were signiﬁcantly increased in the patients with
the lymph-vascular space involvement (Table 3).
3.2. Relationship of Immunohistochemical Expressions of HAS
Isoforms with Serum Levels of HA, the SHAP-HA Complex,
MMP-2, MMP-9 and TIMP-1, and Urine Level of UTI. The
serum levels of the SHAP-HA complex, MMP-9, and TIMP-
1 were higher in the HAS1-positive group than in the HAS1-
negative group. However, the expression of HAS2 and HAS3
was unrelated to them (Table 4). The serum levels of HA
and the SHAP-HA complex had a signiﬁcant correlation
withtheMMP-9, andTIMP-1 inendometrialcancerpatients
(Table 5).
3.3. HAS, HA, SHAP-HA Complex, UTI, MMP-2, MMP-9,
and TIMP-1 Levels in Relation to the Disease-Free Survival
and Overall Survival. The Kaplan-Meier analysis revealed
that the patients with elevated serum levels of the SHAP-
HA complex and TIMP-1 had a shorter disease-free survival
compared with those with normal levels of them. Also,
the Kaplan-Maier analysis revealed that patients with the








Figure 1: Immunohistochemicalvisualizationof HAS1, HAS2, and HAS3 in endometrioid adenocarcinoma of the uterine corpus (×400).
Table 1: Expression of HAS1, HAS2, and HAS3 in relation to the depth of myometrial invasion, histological grade, and lymph-vascular
space involvement in patients with endometrial cancer.
HAS1 expression HAS2 expression HAS3 expression
Negative Positive Negative Positive Negative Positive
n (N = 21) (N = 29) (N = 18) (N = 32) (N = 21) (N = 29)
Myometrial invasion
Less than half 30 16 14 11 19 14 16
More than half 20 5 15 7 13 7 13
χ2 = 3.96, P = 0.0467 P>0.9999 P = 0.5602
Histological grade
G 1 / G 2 4 0 1 92 11 6 2 4 1 5 2 5
G 3 1 0 2 8 2864
P = 0.1604 P = 0.2947 P = 0.2859
Lymph-vascular space involvement
Absent 28 16 12 10 18 12 16
Present 22 5 17 8 14 9 13
χ2 = 5.99, P = 0.0213 P>0.9999 P = 0.8898














Healthy control 50 52.74 ±23.87 1.884 ±1.418 1.930 ±1.47 707.84 ±124.20 277.76 ±117.68 154.16± 29.37
Endometrial cancer 50 368.23 ±233.28 3.294 ±2.209 7.004±15.044 703.94 ±182.54 736.40 ±524.24 223.80 ±100.79
P<0.0001 P = 0.0002 P = 0.0197 P = 0.9009 P<0.0001 P<0.0001
Values are shown as mean ± SD.Obstetrics and Gynecology International 5
Table 3: Serum HA, SHAP-HA complex, MMP-2, MMP-9, TIMP-1, and UTI in relation to the depth of myometrial invasion, histological















Less than half 30 236.94 ± 145.14 2.151 ± 2.030 5.737± 13.679 720.03± 197.67 598.90± 439.17 199.27± 81.09
More than half 20 565.18 ± 200.37 5.009 ± 3.888 8.905± 17.080 679.80± 158.96 942.65± 582.89 260.60 ±117.41
P<0.0001 P = 0.0014 P = 0.4713 P = 0.4508 P = 0.0215 P = 0.0336
Histological grade
G1/G2 40 295.39 ± 180.95 2.443 ± 2.397 4.422± 11.565 699.50± 186.84 694.58± 504.76 209.40± 92.94
G3 10 659.63 ± 191.00 6.698 ± 3.883 17.330± 22.462 721.70± 172.34 903.70± 594.45 281.40 ±115.21
P<0.0001 P<0.0001 P = 0.0136 P = 0.7347 P = 0.2635 P = 0.0421
Lymph-vascular space
involvement
Absent 28 247.75 ± 147.98 2.340 ± 2.838 2.107 ± 1.767 682.32± 185.10 575.71± 328.58 179.75± 36.44
Present 22 521.57 ± 234.18 4.508 ± 3.304 13.236± 21.246 731.46± 179.66 940.91± 651.32 279.86 ±126.95
P<0.0001 P = 0.0161 P = 0.0080 P = 0.3500 P = 0.0129 P = 0.0002
Values are shown as mean ± SD.
Table 4: Serum HA, SHAP-HA complex, MMP-2, MMP-9, TIMP-1, and UTI in relation to the expression of HAS1, HAS2, and HAS3 in















Negative 21 298.22 ±154.04 1.168 ±0.917 2.390 ±2.047 719.10 ±207.79 504.76 ±205.00 183.38± 67.60
Positive 29 418.93 ±268.23 4.833 ±3.403 10.345 ±19.119 692.97 ±164.84 904.14 ±617.70 253.07 ±111.36
P = 0.0705 P<0.0001 P = 0.0643 P = 0.6223 P = 0.0065 P = 0.0142
HAS2 expression
Negative 18 349.8 ±216.78 2.851 ±2.624 3.756 ±5.973 734.22 ±212.04 787.28 ±525.09 244.44 ±120.89
Positive 32 378.6 ±244.82 3.543 ±3.511 8.831 ±18.127 686.91 ±164.86 707.78 ±525.09 212.19± 87.5
P = 0.6796 P = 0.4694 P = 0.2563 P = 0.3845 P = 0.6118 P = 0.2819
HAS3 expression
Negative 21 344.49 ±242.18 3.950 ±3.684 8.010 ±16.122 744.57 ±157.21 798.76 ±625.46 252.67 ±122.38
Positive 29 385.43 ±229.38 2.819 ±2.778 6.276 ±14.460 674.52 ±196.27 691.24 ±443.27 202.90± 77.48
P = 0.5061 P = 0.2226 P = 0.6919 P = 0.1832 P = 0.4798 P = 0.0848
Values are shown as mean ± SD.
had a signiﬁcantly shorter disease-free survival (Figure 2).
The multivariate analysis revealed that the SHAP-HA com-
plex was the signiﬁcant independent variable for the disease-
free survival of endometrial cancer patients (Table 6).
The Kaplan-Meier analysis revealed that the patients with
elevated serum level of the SHAP-HA complex had a sig-
niﬁcantly shorter overall survival although no signiﬁcant
diﬀerence was found in relation with the serum TIMP-1
levels, depth of myometrial invasion, and histological grade
(Figure 3). However, no signiﬁcant variable was observed in
the multivariate analysis for overall survival (Table 7).
4.Discussion
The multistage process of tumor invasion and metastasis
dependsonseveralmechanisms, includingthestimulationof
cell growthby growthfactors, destructionoftheextracellular
matrix by proteolytic enzymes [26], neovascularization due
to the presence of angiogenic factors [27, 28], and cell-to-
cell or stromal cell interaction regulated by cell adhesion
molecules and pericellular matrix molecules.
Signiﬁcantly increased levels of HA are often associated
with certain types of human tumors, and the levels of HA in6 Obstetrics and Gynecology International
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Figure 2: Disease-free survival in endometrial cancer patients was analyzed by the Kaplan-Meier method and log-rank test. The patients
with the deeper myometrial invasion, poorly diﬀerentiated tumor, elevated serum level of the SHAP-HA complex, and elevated serum level
ofTIMP-1hadasigniﬁcantlyshorterdisease-freesurvival.ThemaximalnormallevelinserumoftheSHAP-HAcomplexinserumwasdeter-
mined as 4.7U/mL for the SHAP-HA complex and as 212.9ng/mL for TIMP-1, which were a value of the mean + 2SD in 50 healthy women.
Table 5: Correlationship between the serum HA, SHAP-HA com-
plex, MMP-2, MMP-9, TIMP-1, and UTI in patients with endome-
trial cancer.
Variables rP value
HA and SHAP-HA complex 0.466 0.0005
HA and UTI 0.306 0.0305
HA and MMP-2 0.007 0.9635
HA and MMP-9 0.345 0.0137
HA and TIPM-1 0.364 0.0089
SHAP-HA complex and UTI 0.235 0.1004
SHAP-HA complex and MMP-2 0.066 0.6523
SHAP-HA complex and MMP-9 0.455 0.0008
SHAP-HA complex and TIMP-1 0.396 0.0041
UTI and MMP-2 −0.061 0.6739
UTI and MMP-9 0.071 0.6242
UTI and TIMP-1 0.255 0.0736
MMP-2 and MMP-9 0.032 0.827
MMP-2 and TIMP-1 0.386 0.0053
MMP-9 and TIMP-1 0.677 <0.0001
the sera of some cancer patients are signiﬁcantly higher than
those of normal individuals [7, 29, 30]. Although increased
HA synthesis isnot auniversal characteristic of tumors,there
seems to be an overall tendency for transformed cells to
exhibit higher levels of HA production [31]. In addition, a
close relationship has been demonstrated between HA pro-
duction and malignant phenotypes, such as invasiveness
[32]. Our group and another group found that highly meta-
static cell lines release more HA into culture medium than
less metastatic variants [6]. Furthermore, Zhang et al. [33]
reported that HA on the surface of tumor cells is correlated
with metastatic behavior.
HA has either directly or indirectly been implicated in
cell adhesion, motility, growth, and diﬀerentiation[34]. HA-
binding proteins regulate these cellular behaviors by inter-
acting with HAand forming the HApericellular matrix [35].
Increased matrix deposition of HA may favor tumor growth
and invasion by increasing tissue hydration and providing a
suitable environment for cell migration analogous to embry-
onic cell movement.Other mechanisms may also help tumor
growth and invasion. For example, the HA pericellular coat
may reduce the access and attack of immune cells to tumor
cells [36]. Tumor cells are surrounded by a thick pericellular
coat that is sensitive to hyaluronidase. The removal of this
coat may allow lymphocytes to exert their cytolytic eﬀect on
tumor cells. Additionally, partially degraded HA fragmentsObstetrics and Gynecology International 7







Less than half (n = 30)






0 20 40 60 80 100 120 140
G1/G2 (n = 40)












0 20 40 60 80 100 120 140
SHAP-HA complex ≤4.7U/mL (n = 34)












0 20 40 60 80 100 120 140
TIMP-1 ≤ 212.9U/mL0 (n = 31)












Figure 3: Overall survival in endometrial cancer patients was analyzed by the Kaplan-Meier method and log-rank test. The patients with
elevated serum level of the SHAP-HA complex had a signiﬁcantlyshorter overall survival.
Table 6: Hazard ratios for disease-free survival with 95% CIs ad-
justed for HAS, HA, SHAP-HA complex, UTI, MMP-2, MMP-9,
TIMP-1,andtheclinicopathologicalmanifestationsinpatientswith
endometrial cancer.
Variables Hazard ratio 95% CI P value
Age 1.036 0.866–1.238 0.7020
Myometrial invasion
(more than half) 79.594 0.194–3261.041 0.1155
Histological grade
(G3) 3.407 0.146–79.578 0.4458
Lymph-vascular space
involvement 0.892 0.010–77.881 0.9602
HAS1 expression 0.213 0.002–23.731 0.5203
HAS2 expression 0.273 0.010–7.258 0.4380
HAS3 expression 0.132 0.002–7.961 0.3325
HA 0.990 0.973–1.007 0.2440
SHAP-HA complex 1.773 1.010–3.111 0.0461
UTI 1.084 0.981–1.198 0.1146
MMP-2 0.993 0.976–1.011 0.4693
MMP-9 1.000 0.998–1.002 0.9204
TIMP-1 1.008 0.984–1.034 0.5074
promoteangiogenesis, an important host contributionto tu-
mor cell viability [37].
Our previous study [38] demonstrates that HA synthe-
sized by HAS1 is associated with tumor neovascularization
and predicts tumor aggressiveness and patient survival in
ovarian cancer. Yamada et al. [39] reported that elevated
transcription levels of the HAS1 gene correlated with poor
prognosis of human colon cancer. Anttila et al. [40]r e p o r t e d
that elevated levels of stromal HA indicate that the tumor is
aggressive and predict poor disease outcome in ovarian can-
cer patients, especially those with serous tumors. Kayastha
et al. [41] reported that CD44 expression is associated with
the spread of ovarian cancer and is an independent predictor
of survival. HA contributes to tumor growth, invasion, and
metastasis through cell proliferation, movement, adhesion,
and angiogenesis. It is possible that these functions of HA
depend on the overexpression of the HAS genes.
In our previous report [38] and the present study, the
serum levels of HA and the SHAP-HA complex were
both higher in the endometrial cancer group than in the
healthy control group, and the increased synthesis of HA in
endometrial cancer tissue appeared to depend on the high
expression of HAS1. This ﬁnding suggests that increased HA
reacts with ITI, resulting in the increased levels of the SHAP-
HA complex. In addition, the serum levels of HA and the
SHAP-HA complex in those cancer group were found to be
increased in accordance with the depth of myometrial inva-
sion and lymph-vascular space involvement [38], indicating8 Obstetrics and Gynecology International
Table 7:Hazardratiosforoverallsurvivalwith95%CIsadjusted for
HAS, HA, SHAP-HA complex, UTI, MMP-2,MMP-9,TIMP-1, and
the clinicopathological manifestationsin patients with endometrial
cancer.
Variables Hazard ratio 95% CI P value
Age 0.848 0.583–1.232 0.3859
Myometrial invasion
(more than half) 3.846 0.027–544.845 0.5940
Histological grade
(G3) 0.007 <0.001–7458.166 0.4799
Lymph-vascular space
involvement 0.002 <0.001–175.169 0.2913
HAS1 expression — — —
HAS2 expression — — —
HAS3 expression — — —
HA 1.003 0.984–1.023 0.7456
SHAP-HA complex 3.417 0.820–12.075 0.0947
UTI 0.297 0.055–1.610 0.1591
MMP-2 1.010 0.992–1.029 0.2790
MMP-9 1.004 0.996–1.013 0.3126
TIMP-1 — — —
that the increased levels of HA and the SHAP-HA complex
are related to tumor invasion and metastasis.
The present study has also demonstrated that the serum
levels of MMP-9 and TIMP-1 were signiﬁcantly higher in
the endometrial cancer group than in the healthy control
group, and serum MMP-9 was elevated according to the
depth of myometrial invasion and lymph-vascular space
involvement.Therearesomereportssuggestingthathyaluro-
nan upregulates MMP-9 and TIMP-1 expressions via CD44
signaling [42, 43]. Peng et al. [44]h a v es h o w nt h a t ,i n
culture of human breast carcinoma cells, antibody-mediated
CD44 cross-linking resulted in the colocalization of CD44
and MMP-9, which may augment the level of MMP-9 in
the membrane, possibly implicated in the increased capacity
of tumor invasion and metastasis. We have shown that
SHAP appears to potentiate the interaction resulting in
the increased avidity of HA to CD44 and have suggested
that SHAP could function in activating CD44 signaling by
increasing the interaction with HA [45]. It is likely therefore
that the high serum levels of MMP-9 may be consequential
reﬂection ofthe increased levels ofthe SHAP-HAcomplex in
endometrial cancer, which explains the present observation
that the elevated levels of SHAP-HA complex had a shorter
disease-free survival time compared to those patients with
normal levels of SHAP-HA complex.
MMPs are known to be inhibited by naturally occurring
TIMPs [46]. Thus, TIMPs are also important factors to reg-
ulate cancer cell invasion and metastasis. For one example,
Runx3 has been shown to suppress gastric cancer metastasis
through the inactivation of MMP-9 by the upregulation of
TIMP-1 [47]. However, TIMPs were found to have multiple
functions [48]. It not only regulates activity of MMPs as
their natural tissue inhibitors as described above, but also
stimulates tumor growth and malignant transformation. For
example, tissue levels of TIMPs in gastric adenocarcinoma
[49] and their serum levels in colorectal cancer [50]a r e
reported to reﬂect roles in predicting the aggressive behav-
iors of those cancer cells, together with those of MMP-
9, suggesting that MMP-9 expression is an independent
diagnostic valuable for tumor malignancy. Or, the higher
levelsofTIMPs couldreﬂect some physiologicalmechanisms
of TIMPs expressions to regulate MMPs expressions and
activities. Considering those multi- and variable functions of
TIMPs, it is reasonable that the present analysis has revealed
that the SHAP-HA complex and TIMP-1 were a signiﬁcant
independent variable predicting a shorter disease-free sur-
vival.
5.Conclusion
The elevation of serum SHAP-HA complex depended on
the HAS1 expression and the SHAP-HA complex is a useful
marker to predict disease recurrence in endometrial cancer
patients.BecausethelevelsoftheSHAP-HAcomplexshowed
a signiﬁcant positive correlation with the levels of MMP-
9 and TIMP-1, the SHAP-HA complex may promote the
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